Further indications for dacarbazine as part of a combination chemotherapy are:

Fotemustine and dacarbazine should not be used concomitantly.

Dacarbazine-solutions are prepared immediately before use.

No special recommendations for the use of dacarbazine in the paediatric age group can be given until further data become available.

Further indications for Dacarbazine as part of combination chemotherapy are:

Further indications for Dacarbazine as part of combination chemotherapy are:

Dacarbazine-solutions are prepared immediately before use.

Dacarbazine solutions should be prepared immediately before use.

This toxicity has been observed mostly when Dacarbazine for Injection has been administered concomitantly with other anti-neoplastic drugs: however, it has also been reported in some patients treated with Dacarbazine for Injection alone.

The most common grade ≥3 treatment-related adverse events reported in ≥10% patients were neuropathy (ABRAXANE: 25% vs. dacarbazine: 0%), neutropenia (ABRAXANE: 20% vs. dacarbazine: 10%).

The most common grade-3 or greater, treatment-related adverse events were neuropathy (Abraxane: 25% vs. dacarbazine: 0%) and neutropenia (Abraxane: 20% vs. dacarbazine: 10%).

The most common grade ≥3 treatment-related adverse events reported in ≥10% patients were neuropathy (ABRAXANE: 25% vs. dacarbazine: 0%), neutropenia (ABRAXANE: 20% vs. dacarbazine: 10%).

Dacarbazine is considered not to show an antineoplastic effect by itself.

Further indications for dacarbazine as part of a combination chemotherapy are:

This toxicity has been observed when dacarbazine has been administered concomitantly with other antineoplastic drugs; however, it has also been reported in some patients treated with dacarbazine alone.